重组人粒细胞集落刺激因子在恶性肿瘤化疗中的应用

目的评价基因重组人粒细胞集落刺激因子（ｒｅｃｏｍｂｉｎａｎｔｈｕｍａｎｇｒａｎｕｌｏｃｙｔｅｃｏｌｏｎｙ－ｓｔｉｍｕｌａｔｉｎｇｆａｃｔｏｒ，ｒｈＧ－ＣＳＦ）对恶性肿瘤化疗后白细胞（ＷＢＣ）和中性粒细胞（ＡＮＣ）减少的防治作用。方法全组５２例；对照组２０例，为化疗后ＷＢＣ计数在１．０×１０９／Ｌ～３．０×１０９／Ｌ之间者，采用利血生、鲨肝醇等一般性治疗及中医药治疗；治疗组３２例，为化疗后ＷＢＣ计数＜３．０×１０９／Ｌ者，其中包括ＷＢＣ计数＜１．０×１０９／Ｌ，采用一般性治疗加ｒｈＧ－ＣＳＦ治疗。结果治疗组ＷＢＣ和ＡＮＣ在治疗后恢复至正常所需时间明显小于对照组（Ｐ＜０．０１）。结论ｒｈＧ－ＣＳＦ可明显缩短ＷＢＣ和ＡＮＣ降至正常以下持续的时间，促进早日恢复，使化疗可以如期进行     

颗粒细胞集落刺激因子在白细胞减少血液病中的应用

对２４例恶性血液病患者于化疗结束后次日应用颗粒细胞集落刺激因子（ｒｈＧ－ＣＳＦ）１００μｇ·ｄ－１，皮下注射，连用５～７天，最短３天，最长２０天。并选择同期恶性血液病化疗２０例作为对照组。结果发现化疗后末梢血ＷＢＣ＞４．０×１０９·Ｌ－１或ＡＮＣ＞２．０×１０９·Ｌ－１；恢复时间，治疗组明显短于对照组（Ｐ＜０．０１）；治疗组化疗后发热并发感染的天数短于对照组（Ｐ＜０．０５）。在治疗组患者中未出现明显副作用。表明ｒｈＧ－ＣＳＦ有使化疗后患者末梢血ＷＢＣ、特别是ＡＮＣ恢复加快，减少感染的作用。     

溶栓治疗急性心肌梗塞中白细胞计数与心肌酶峰值的关系

为探讨急性心肌梗塞（ＡＭＩ）溶栓治疗对心肌酶峰值的影响及白细胞计数（ＷＢＣ）与ＡＭＩ的关系，对２１１例ＡＭＩ患者随机分成尿激酶（ＵＫ）治疗组与常规治疗对照组，测定静脉血ＷＢＣ及监测心肌酶。结果显示：常规治疗患者ＷＢＣ增高组（＞１０×１０９／Ｌ）心肌酶（ＣＫ．ＣＫＭＢ）峰值明显高于ＷＢＣ正常组（≤１０×１０９／Ｌ）（Ｐ＜０．００１）；溶栓治疗患者ＷＢＣ增高组与ＷＢＣ正常组心肌酶峰值无显著差异（Ｐ＞０．０５）。溶栓组心肌酶峰值显著高于对照组（Ｐ＜０．０１）。结论：非溶栓治疗患者，ＷＢＣ升高是心肌坏死程度指标。溶栓治疗患者心肌酶峰值增高是心肌再灌注特有指标之一，溶栓治疗阻断在ＡＭＩ中ＷＢＣ的对心肌损伤作用     

国产重组人粒细胞集落刺激因子治疗化疗后粒细胞减少症的临床疗效观察

目的：评价国产重组人粒细胞集落刺激因子（ｒｈＧＣＳＦ）治疗肿瘤化学治疗后引起的粒细胞减少症的临床疗效和不良反应。方法：采用随机、自身交叉的对照方法观察了６０例恶性肿瘤化疗患者应用国产ｒｈＧＣＳＦ的效果。结果：国产ｒｈＧＣＳＦ具有明显的升高中性粒细胞作用,表现为：①合并使用ｒｈＧＣＳＦ周期（Ａ周期）ＷＢＣ最低值、中性粒细胞绝对计数（ＡＮＣ）最低值明显高于单纯化疗周期（Ｂ周期）;②Ａ周期ＷＢＣ＜２０×１０９／Ｌ、＜３０×１０９／Ｌ、＜４０×１０９／Ｌ持续天数显著缩短;ＡＮＣ＜０５×１０９／Ｌ、＜１０×１０９／Ｌ、＜１５×１０９／Ｌ、＜２０×１０９／Ｌ持续天数显著缩短;③Ａ周期化疗序日ｄ２１的ＷＢＣ值、ＡＮＣ值明显高于Ｂ周期;④Ａ周期化疗序日ｄ２１ＷＢＣ＜４０×１０９／Ｌ的病例数、ＡＮＣ＜２０×１０９／Ｌ的病例数明显少于Ｂ周期。使用国产ｒｈＧＣＳＦ不良反应轻微。结论：国产ｒｈＧＣＳＦ是一种安全有效的治疗粒细胞减少症的药物。     

重组人粒细胞集落刺激因子在造血系统疾病中的应用

对因急性白血病（ＡＬ）、恶性淋巴瘤、多发性骨髓瘤（ＭＭ）联合化疗及其他药物所致中性粒细胞缺乏症１９例患者予以重组人粒细胞集落刺激因子（ｒｈＧ－ＣＳＦ）治疗，中性粒细胞绝对数（ＡＮＣ）达显效、有效分别为１３例（６８．４２％），２例（１０．５２％），总有效率７８．９４％；所需中位时间分别为８，１４天。治疗后ＡＮＣ增值１．５７～１１３６０倍，白细胞（ＷＢＣ）、ＡＮＣ达显效、有效时间明显缩短（Ｐ＜０．００５）。随着ＡＮＣ增值，患者感染、使用广谱抗生素及化疗间歇时间均缩短，对患者及时进行化疗、安全渡过化疗后骨髓抑制期，进一步杀灭体内残存肿瘤细胞及缩减整体医疗费用具有重要意义。     

香菇多糖对恶性血液病患者免疫功能的调控作用

观察香菇多糖配合化疗治疗对恶性血液病患者细胞免疫功能的影响。恶性血液病６８例（ＡＬ３０例，ＣＬ９例，ＭＬ２９例）分为两组，香菇多糖治疗组４４例，单纯化疗组２４例，香菇多糖组治疗后ＣＤ４、ＣＤ４／ＣＤ８及ＮＫ细胞活性明显提高，ＣＤ８及ＨＬＡＤＲ抗原活性减低（Ｐ＜０．０５），治疗有效率及Ｈｂ、ＷＢＣ亦高于单纯化疗组（Ｐ＜０．０５）。结果提示，香菇多糖配合化疗可提高恶性血液病细胞免疫功能及机体抗肿瘤活性，并改善临床症状及提高化疗疗效     

小剂量全反式维甲酸治疗急性早幼粒细胞白血病15例

１９９５年２月～１９９８年１２月,我们应用小剂量全反式维甲酸（ＡＴＲＡ）治疗急性早幼粒细胞白血病（ＡＰＬ）１５例,疗效满意,现报告如下。１　材料和方法１．１　病例　根据病史、体征,经外周血和骨髓象确定诊断。１５例中男９例,女６例,年龄１９～５３岁,平均３２岁。１．２　方法　ＡＴＲＡ２５ｍｇ／（ｍ２·ｄ）,分２次口服,治疗前ＷＢＣ＞１０×１０９／Ｌ者开始加小剂量化疗,ＷＢＣ＜１０×１０９／Ｌ者ＡＴＲＡ治疗后ＷＢＣ＞１０×１０９／Ｌ时再加小剂量化疗（高三尖杉酯硷１ｍｇ／ｄ静滴１４～２１ｄ）,ＣＲ后继…     

重组人粒细胞集落刺激因子在治疗急性髓细胞白血病中的应用

目的：报告重组人粒细胞集落刺激因子（ｒｈＧ－ＣＳＦ）在急性细胞白血病（ＡＭＬ）治疗中的应用及其疗效观察：方法应用中等剂量、短疗程（３－５天）ｒｈＧ－ＣＳＦ治疗ＡＭＬ２８例,并与同期未用ｒｈＧ－ＣＳＦ治疗的ＡＭＬ２８例进行比较。结果：ｒｈＧ－ＣＳＦ能显著缩短化疗后中性粒细胞计数（ＡＮＣ）的低下期及感染的持续时间,同时能明显减少化疗后的输血用量。     

促粒素防治化疗后白细胞减少症的疗效观察

研究促粒素（ｒｈＧ－ＣＳＦ）对化疗后白细胞减少的防治作用。采用随机分组、自身交叉对比的方法,观察两组共６０例患者在化疗期间应用促粒素的疗效。结果提示,促粒素可以促进化疗患者ＷＢＣ和ＡＮＣ的恢复,缩短ＷＢＣ和ＡＮＣ减少的持续时间,降低感染率,可以作为肿瘤化疗中提高剂量强度的有效的辅助药物。     

温血心停跳液与冷晶体心停跳液对狗心率变异性的影响

为探讨体外循环（ＣＰＢ）导致心脏植物神经系统（ＣＡＳ）损伤的机理，了解温血心停跳液能否防止ＣＰＢ后心率变异性（ＨＲＶ）的降低，采用对照方法观察了温血心停跳液与冷心停跳液对狗ＨＲＶ的影响，结果显示：ＣＰＢ后温血心停跳液组（ＷＢ组）和冷晶体心停跳液组（ＣＣ组）的全频谱（ＴＰ），低频（ＬＦ）和高频（ＨＦ）均较术前明显降低（Ｐ〈０．０５），而且ＣＣ组比ＷＢ 降低更明显（Ｐ〈０．０５），且ＬＦ／ＨＦ在组内及     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…